Meanwhile, GLP-1RAs showed a trend towards a reduced risk for nine respiratory diseases, although not reaching statistical significance, including pneumonia (RR 0.89, 95% CI 0.781.00, p = 0.05
Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
These findings support more research, but they do not show that 5-Amino-1MQ causes weight loss, more energy, or better health in people
So sometimes it's enough that people actually throw up and pass out
If alternative therapy is needed, caution should be exercised when considering other GLP-1 receptor agonists due to potential cross-reactivity